Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Executive Summary

• Neurothera Labs Inc. announced that the Israel Patent Office has granted a patent for its proprietary opioid‑N‑acylethanolamine (PEA) combination technology.
• The Israeli patent adds to existing patents in Europe, Japan, Australia and Canada, expanding global IP protection for the company’s opioid‑sparing platform.
• Pre‑clinical data show that the oxycodone + PEA formulation enhances analgesic efficacy while reducing typical opioid side effects, supporting the commercial potential of the technology.

Key Details

• Patent Grant: Israel Patent Office issued a patent covering methods and formulations that combine opioids with N‑acylethanolamines (e.g., palmitoylethanolamide) to potentiate therapeutic effects and reduce tolerance, dependence, and gastrointestinal issues.
• Global IP Portfolio: The new Israeli patent joins previously granted patents in Europe, Japan, Australia, and Canada, providing broader protection for the proprietary platform.
• Pre‑clinical Study Findings:
• Compared oxycodone alone vs. oxycodone + PEA across multiple concentrations in regulatory‑compliant animal models.
• Combination demonstrated:
  • Reduced psychoactive adverse events associated with oxycodone.
  • Prolonged analgesic duration at all tested doses.
• Market Context: Global oxycodone market valued at approximately $5.5–$5.7 billion in 2024, highlighting the commercial relevance of an opioid‑sparing solution.
• Potential Benefits: The “opioid‑sparing” effect could lower required opioid dosages, potentially mitigating risks of misuse, addiction, respiratory depression, and other side effects.
• CEO Quote: Oz Adler, CEO, stated that the patent validates the company’s approach to delivering strong pain relief without compromising patient safety and represents an important achievement.

Notable Quotes

“We believe that granting a patent based on experiments that have shown such an outcome and validate the advantages of our proprietary opioids and N‑acylethanolamines combination in maintaining immediate and strong pain relief effect without compromising patients’ safety is an important achievement of the Company.” – Oz Adler, Chief Executive Officer

All boilerplate, forward‑looking disclaimer text, and contact information have been omitted for clarity.